(Alliance News) - Renalytix PLC on Wednesday published some data, which has demonstrated that KidneyIntelX has "broad implications for winning the war on chronic kidney disease."

Renalytix is a London-based kidney health-focused diagnostics company.

Renalytix noted the publication of Real World Evidence after 12 months of follow-up in 2,569 patients with Type 2 diabetes and diabetic kidney disease.

It noted that results demonstrated a 61% increase in preventative drug prescriptions among patients in the high-risk group and improved specialist referrals, which can significantly reduce overall cost of care and improve patient outcomes.

"The demonstrated benefits of KidneyIntelX early risk assessment at one year are significant and go to the core of chronic disease preventative medicine. This real-world data highlights the critical importance of early preventative care and the ability to better control cost and outcomes through efficient electronic deployment of KidneyIntelX bioprognosis," said Michael Donovan, chief medical officer at Renalytix.

"We look forward to continuing published data releases in coming months in order to support our belief that KidneyIntelX provides actionable information leading to preventative care and improving healthcare outcomes."

Shares in Renalytix were down 3.6% at 14.95 pence each in London on Wednesday afternoon.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.